ISO 10993 Biocompatibility Testing: A Complete Technical Guide to Biological Evaluation of Medical D

ISO 10993 biocompatibility testing is the internationally recognized framework for evaluating the biological safety of medical devices, materials, and their extracts before patient contact. This technical guide explains the ISO 10993 test matrix, sample preparation requirements, core biological endpoints, and testing methods to help manufacturers plan compliant biological evaluations for FDA, EU MDR, and other global regulatory submissions.

Technical Overview

ISO 10993 is a multi-part series of international standards governing the biological evaluation of medical devices. It provides a structured, risk-based framework for assessing whether a device, its materials, or its extractable chemicals pose unacceptable biological risks to patients. The standard series is maintained by ISO/TC 194 and is harmonized with major regulatory frameworks worldwide, including the FDA in the United States, the EU Medical Device Regulation (MDR), and national programs in China, Japan, and Canada.

The foundation of the evaluation is ISO 10993-1, which defines the biological evaluation as a risk management process rather than a simple checklist of tests. Under the 2018 revision, the standard emphasizes a physical-chemical characterization first approach, requiring manufacturers to understand material composition, extractables and leachables, and degradation behavior before selecting biological tests. Testing is then chosen based on two key classification criteria:

• Nature of body contact: surface-contacting devices (skin, mucous membranes, breached surfaces), externally communicating devices (indirect blood path, tissue, bone, dentin), and implant devices (tissue, bone, blood).
• Contact duration: limited exposure (24 hours or less), prolonged exposure (24 hours to 30 days), and permanent contact (more than 30 days).

The intersection of contact category and contact duration determines the recommended endpoints, which typically include cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation effects, and hemocompatibility. A documented Biological Evaluation Plan (BEP) and Biological Evaluation Report (BER) are essential deliverables of the process.

Testing Samples

Final Device Samples

Whenever feasible, testing should be performed on the final product in its final manufacturing condition, including all processing, cleaning, and sterilization steps. Sterilization methods such as ethylene oxide, gamma irradiation, or electron beam can alter material chemistry or generate residuals, so samples tested in an unsterilized state may not represent the device as used clinically.

Material Extracts

For most in vitro and some in vivo endpoints, testing is conducted on aqueous and non-aqueous extracts prepared according to ISO 10993-12. Polar media (such as physiological saline or culture medium) and non-polar media (such as vegetable oil) are used in parallel to solubilize both hydrophilic and hydrophobic extractables. Extraction is typically performed at a standardized surface-area-to-volume or mass-to-volume ratio, for example 6 cm²/mL for thin polymer films, 3 cm²/mL for thicker sections, or approximately 0.1 to 0.2 g/mL for irregularly shaped materials.

Sample Preparation and Extraction Conditions

ISO 10993-12 provides accelerated extraction conditions intended to simulate or exaggerate clinical use. Common validated conditions include:

• 37°C for 24 hours (physiological simulation)
• 37°C for 72 hours (extended physiological extraction)
• 50°C for 72 hours (accelerated extraction)
• 70°C for 24 hours (accelerated extraction)
• 121°C for 1 hour (exaggerated extraction for heat-stable materials)

The selected condition must be justified relative to the intended use of the device and must not degrade the material in a way that would not occur clinically. Negative controls (such as high-density polyethylene) and positive controls (such as extracts containing latex or zinc dibutyldithiocarbamate) are run concurrently to demonstrate assay sensitivity.

Testing Items

The ISO 10993 endpoint matrix maps biological effects to specific standard parts. The core testing items most frequently required for regulatory clearance are summarized below.

Cytotoxicity (ISO 10993-5)

In vitro cytotoxicity is the baseline screen for nearly all device categories regardless of contact nature or duration. Mammalian cells (commonly L929 mouse fibroblasts) are exposed to device extracts, to the device directly, or through an agar or filter diffusion barrier. Quantitative assays such as MTT or neutral red uptake measure cell viability, with a reduction greater than 30 percent (viability below 70 percent) constituting a failure.

Sensitization (ISO 10993-10)

Sensitization testing evaluates the potential for Type IV delayed hypersensitivity reactions. The guinea pig maximization test (GPMT) and the closed-patch (Buehler) method remain widely accepted, while the murine local lymph node assay (LLNA) offers a refined alternative with quantitative endpoint measurement and reduced animal use.

Irritation and Intracutaneous Reactivity (ISO 10993-23)

Irritation testing assesses localized inflammatory responses such as erythema, edema, or mucosal damage. The intracutaneous reactivity test in rabbits involves injection of polar and non-polar extracts, with scoring of dermal reactions. ISO 10993-23:2021 now governs irritation, including validated in vitro alternatives such as reconstructed human epidermis (RhE) models for skin irritation, reflecting the industry shift toward non-animal methods.

Acute Systemic Toxicity (ISO 10993-11)

This test evaluates harmful effects occurring shortly after a single exposure to device extracts, typically via intravenous (polar extract) and intraperitoneal or oral (non-polar extract) routes in mice. Animals are observed for clinical signs, body weight change, and mortality over 72 hours.

Genotoxicity, Carcinogenicity, and Reproductive Toxicity (ISO 10993-3)

Genotoxicity is evaluated using a battery of in vitro assays, typically the bacterial reverse mutation (Ames) test plus a chromosomal aberration assay or mouse lymphoma assay. In vivo genotoxicity, carcinogenicity bioassays, and reproductive or developmental toxicity studies are required only when triggered by the risk assessment, such as known mutagenic leachables or long-term permanent implants.

Hemocompatibility (ISO 10993-4)

For blood-contacting devices, hemocompatibility testing evaluates categories such as thrombosis, coagulation, platelets, hematology, and the complement system. The in vitro hemolysis assay is the most common screen, generally expecting a hemolysis rate below 5 percent, with supplemental assays selected according to blood contact duration and flow conditions.

Subacute, Subchronic, and Chronic Toxicity (ISO 10993-11)

Repeated-dose systemic toxicity studies (14 to 28 days or longer) assess effects from prolonged exposure to device extracts or materials, including clinical pathology, gross necropsy, and histopathology. These studies are typically triggered for prolonged and permanent contact devices.

Implantation Effects (ISO 10993-6)

Implantation testing evaluates the local tissue response to device materials placed in direct contact with living tissue, typically muscle or bone in rodents or rabbits. Histopathological comparison of the local biological response at the implant site against a control material forms the basis of the evaluation.

Chemical Characterization and Degradation (ISO 10993-18, 10993-17, 10993-9/13/14/15)

Chemical characterization using extractables and leachables analysis is now the cornerstone of the biological evaluation. Toxicological risk assessment compares estimated patient exposure against health-based exposure limits. For absorbable or degrading materials, additional studies quantify degradation products and their kinetics.

Testing Methods

In Vitro Methods

In vitro techniques form the first tier of the biological evaluation and include the direct contact test, the indirect contact agar diffusion and filter diffusion tests, and the extract (elution) test. Quantitative colorimetric readouts such as MTT are preferred for objective dose-response assessment, and in vitro skin and ocular irritation models are increasingly accepted as replacements for corresponding animal tests.

In Vivo Methods

In vivo studies are conducted only when in vitro data are insufficient, consistent with the animal welfare principles of ISO 10993-2. Standard methods include the GPMT and LLNA for sensitization, intracutaneous injection in rabbits for reactivity, single-dose extract administration in mice for acute systemic toxicity, and surgical implantation followed by histopathology for local tissue effects. GLP compliance is expected for pivotal studies supporting regulatory submissions.

Analytical Chemistry Methods

Chemical characterization relies on a complementary suite of instrumentation to identify and quantify extractables and leachables:

• Gas chromatography-mass spectrometry (GC-MS) for volatile and semi-volatile organics
• Liquid chromatography-mass spectrometry (LC-MS/MS) for non-volatile and polar organics
• Inductively coupled plasma mass spectrometry or optical emission spectrometry (ICP-MS/ICP-OES) for elemental impurities and heavy metals
• Headspace GC for residual solvents and ethylene oxide residuals
• Ion chromatography for inorganic anions and cations

Identified compounds are evaluated through a toxicological risk assessment using tolerable exposure values, margins of safety, and the threshold of toxicological concern (TTC) framework described in ISO 10993-17.

Applications

ISO 10993 biocompatibility testing supports the safe development and market entry of virtually every category of medical device and combination product. Typical applications include:

• Vascular catheters, guidewires, stents, and grafts requiring hemocompatibility assessment
• Orthopedic implants, spinal devices, and bone cement evaluated via implantation and chronic endpoints
• Wound dressings, surgical drapes, adhesive tapes, and electrode gels for skin contact evaluation
• Syringes, IV administration sets, and blood collection tubes as indirect blood path devices
• Dental materials, restoratives, and impression products contacting dentin and oral mucosa
• Infusion pumps, dialyzers, respirator circuits, and other externally communicating equipment
• Absorbable scaffolds and drug-device combination products requiring degradation and E&L studies

Test results documented in a Biological Evaluation Report are essential technical evidence for FDA 510(k) and PMA submissions, EU MDR conformity assessment and CE marking, NMPA registration in China, PMDA applications in Japan, and quality system file support for material or supplier changes. Comparative biocompatibility data also play a key role in justifying equivalency claims when leveraging predicate devices.

FAQ

What tests are typically required for a surface-contacting device with limited contact duration?

Per the ISO 10993-1 matrix, the minimum endpoints for a surface device with limited contact are cytotoxicity, sensitization, and irritation or intracutaneous reactivity. Additional endpoints are added only when the risk assessment identifies specific concerns such as novel materials, patient populations, or chemical leachables.

How long does ISO 10993 biocompatibility testing take?

Timelines vary by endpoint. Cytotoxicity generally requires two to three weeks including sample preparation, sensitization via GPMT requires approximately eight to ten weeks, LLNA around four to six weeks, irritation and acute toxicity around three to four weeks, and implantation studies from several weeks to several months depending on the implantation period. Chemical characterization and toxicological risk assessment typically require four to eight weeks depending on analytical complexity.

Is ISO 10993 testing mandatory for FDA and EU MDR submissions?

Regulators do not blindly require every test in the matrix, but a documented biological evaluation consistent with ISO 10993-1 is expected for any device with patient contact. Both the FDA and EU notified bodies expect a risk-based rationale, robust chemical characterization, and justification for any endpoints omitted or satisfied through existing data.

Can existing data or literature replace new testing?

Yes. ISO 10993-1 explicitly allows the use of material characterization data, supplier information, published literature, and clinical experience from equivalent devices to waive specific tests. The justification must be documented in the Biological Evaluation Plan and Report, and waivers based solely on material specifications without toxicological bridging data are rarely accepted.

What is the acceptance criterion for the cytotoxicity test?

In quantitative assays performed per ISO 10993-5, a test sample is considered non-cytotoxic when mean cell viability remains at or above 70 percent relative to the blank control. Qualitative microscopy grading on a 0 to 4 reactivity scale is used to support, but not replace, the quantitative determination when both are reported.